FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386906467> ?p ?o ?g. }

• W4386906467 endingPage "911" @default.
• W4386906467 startingPage "900" @default.
• W4386906467 abstract "BackgroundInclusion body myositis is the most common progressive muscle wasting disease in people older than 50 years, with no effective drug treatment. Arimoclomol is an oral co-inducer of the cellular heat shock response that was safe and well-tolerated in a pilot study of inclusion body myositis, reduced key pathological markers of inclusion body myositis in two in-vitro models representing degenerative and inflammatory components of this disease, and improved disease pathology and muscle function in mutant valosin-containing protein mice. In the current study, we aimed to assess the safety, tolerability, and efficacy of arimoclomol in people with inclusion body myositis.MethodsThis multicentre, randomised, double-blind, placebo-controlled study enrolled adults in specialist neuromuscular centres in the USA (11 centres) and UK (one centre). Eligible participants had a diagnosis of inclusion body myositis fulfilling the European Neuromuscular Centre research diagnostic criteria 2011. Participants were randomised (1:1) to receive either oral arimoclomol 400 mg or matching placebo three times daily (1200 mg/day) for 20 months. The randomisation sequence was computer generated centrally using a permuted block algorithm with randomisation numbers masked to participants and trial staff, including those assessing outcomes. The primary endpoint was the change from baseline to month 20 in the Inclusion Body Myositis Functional Rating Scale (IBMFRS) total score, assessed in all randomly assigned participants, except for those who were randomised in error and did not receive any study medication, and those who did not meet inclusion criteria. Safety analyses included all randomly assigned participants who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, number NCT02753530, and is completed.FindingsBetween Aug 16, 2017 and May 22, 2019, 152 participants with inclusion body myositis were randomly assigned to arimoclomol (n=74) or placebo (n=78). One participant was randomised in error (to arimoclomol) but not treated, and another (assigned to placebo) did not meet inclusion criteria. 150 participants (114 [76%] male and 36 [24%] female) were included in the efficacy analyses, 73 in the arimoclomol group and 77 in the placebo group. 126 completed the trial on treatment (56 [77%] and 70 [90%], respectively) and the most common reason for treatment discontinuation was adverse events. At month 20, mean IBMFRS change from baseline was not statistically significantly different between arimoclomol and placebo (–3·26, 95% CI –4·15 to –2·36 in the arimoclomol group vs –2·26, –3·11 to –1·41 in the placebo group; mean difference –0·99 [95% CI –2·23 to 0·24]; p=0·12). Adverse events leading to discontinuation occurred in 13 (18%) of 73 participants in the arimoclomol group and four (5%) of 78 participants in the placebo group. Serious adverse events occurred in 11 (15%) participants in the arimoclomol group and 18 (23%) in the placebo group. Elevated transaminases three times or more of the upper limit of normal occurred in five (7%) participants in the arimoclomol group and one (1%) in the placebo group. Tubulointerstitial nephritis was observed in one (1%) participant in the arimoclomol group and none in the placebo group.InterpretationArimoclomol did not improve efficacy outcomes, relative to placebo, but had an acceptable safety profile in individuals with inclusion body myositis. This is one of the largest trials done in people with inclusion body myositis, providing data on disease progression that might be used for subsequent clinical trial design.FundingUS Food and Drug Administration Office of Orphan Products Development and Orphazyme." @default.
• W4386906467 created "2023-09-21" @default.
• W4386906467 creator A5001311437 @default.
• W4386906467 creator A5001954609 @default.
• W4386906467 creator A5004239505 @default.
• W4386906467 creator A5004778599 @default.
• W4386906467 creator A5005382246 @default.
• W4386906467 creator A5006593364 @default.
• W4386906467 creator A5006764987 @default.
• W4386906467 creator A5007436509 @default.
• W4386906467 creator A5007894273 @default.
• W4386906467 creator A5008347070 @default.
• W4386906467 creator A5008787655 @default.
• W4386906467 creator A5009171206 @default.
• W4386906467 creator A5009695382 @default.
• W4386906467 creator A5011268516 @default.
• W4386906467 creator A5012553246 @default.
• W4386906467 creator A5016703264 @default.
• W4386906467 creator A5019347256 @default.
• W4386906467 creator A5021522175 @default.
• W4386906467 creator A5022980917 @default.
• W4386906467 creator A5025582398 @default.
• W4386906467 creator A5027005573 @default.
• W4386906467 creator A5029742789 @default.
• W4386906467 creator A5030869017 @default.
• W4386906467 creator A5031317961 @default.
• W4386906467 creator A5032907512 @default.
• W4386906467 creator A5033438287 @default.
• W4386906467 creator A5033729650 @default.
• W4386906467 creator A5036760740 @default.
• W4386906467 creator A5037255930 @default.
• W4386906467 creator A5037461193 @default.
• W4386906467 creator A5039373481 @default.
• W4386906467 creator A5040996557 @default.
• W4386906467 creator A5042815412 @default.
• W4386906467 creator A5043364831 @default.
• W4386906467 creator A5043784386 @default.
• W4386906467 creator A5045707809 @default.
• W4386906467 creator A5046434091 @default.
• W4386906467 creator A5046451291 @default.
• W4386906467 creator A5047314357 @default.
• W4386906467 creator A5048226565 @default.
• W4386906467 creator A5051045476 @default.
• W4386906467 creator A5051196096 @default.
• W4386906467 creator A5051211055 @default.
• W4386906467 creator A5052141886 @default.
• W4386906467 creator A5055212192 @default.
• W4386906467 creator A5055933495 @default.
• W4386906467 creator A5055953731 @default.
• W4386906467 creator A5057319576 @default.
• W4386906467 creator A5057325944 @default.
• W4386906467 creator A5057927933 @default.
• W4386906467 creator A5060095007 @default.
• W4386906467 creator A5063286565 @default.
• W4386906467 creator A5064526795 @default.
• W4386906467 creator A5064714121 @default.
• W4386906467 creator A5067336037 @default.
• W4386906467 creator A5067612910 @default.
• W4386906467 creator A5069625656 @default.
• W4386906467 creator A5075590091 @default.
• W4386906467 creator A5075995054 @default.
• W4386906467 creator A5077451505 @default.
• W4386906467 creator A5078703656 @default.
• W4386906467 creator A5079096103 @default.
• W4386906467 creator A5079465129 @default.
• W4386906467 creator A5081145634 @default.
• W4386906467 creator A5082799219 @default.
• W4386906467 creator A5084764166 @default.
• W4386906467 creator A5085599616 @default.
• W4386906467 creator A5086689843 @default.
• W4386906467 creator A5086958659 @default.
• W4386906467 creator A5087104312 @default.
• W4386906467 creator A5088142456 @default.
• W4386906467 creator A5089683798 @default.
• W4386906467 creator A5090252124 @default.
• W4386906467 creator A5092912146 @default.
• W4386906467 creator A5092912147 @default.
• W4386906467 creator A5092912148 @default.
• W4386906467 creator A5092912149 @default.
• W4386906467 creator A5092912150 @default.
• W4386906467 creator A5092912151 @default.
• W4386906467 date "2023-10-01" @default.
• W4386906467 modified "2023-10-09" @default.
• W4386906467 title "Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial" @default.
• W4386906467 cites W1986834353 @default.
• W4386906467 cites W1989124659 @default.
• W4386906467 cites W1995588340 @default.
• W4386906467 cites W2020346773 @default.
• W4386906467 cites W2058745880 @default.
• W4386906467 cites W2071698893 @default.
• W4386906467 cites W2115226917 @default.
• W4386906467 cites W2120377396 @default.
• W4386906467 cites W2130106568 @default.
• W4386906467 cites W2150943890 @default.
• W4386906467 cites W2311476251 @default.
• W4386906467 cites W2513570588 @default.
• W4386906467 cites W2612552582 @default.
• W4386906467 cites W2750194920 @default.

• next